$19.44
0.261.36%
At close: -
$19.18
-0.26-1.34%
After Hours: Apr 16, 4:00 PM EDT
Comments
Loading...
Cidara Therapeutics Analyst Ratings and Price Targets | NASDAQ:CDTX | Benzinga
Cidara Therapeutics Inc has a consensus price target of $38 based on the ratings of 8 analysts. The high is $46 issued by Citizens Capital Markets on March 12, 2025. The low is $33 issued by Guggenheim on November 8, 2024. The 3 most-recent analyst ratings were released by Needham, Citizens Capital Markets, and HC Wainwright & Co. on April 10, 2025, March 12, 2025, and March 10, 2025, respectively. With an average price target of $38.67 between Needham, Citizens Capital Markets, and HC Wainwright & Co., there's an implied 101.60% upside for Cidara Therapeutics Inc from these most-recent analyst ratings.
Analyst Firms Making Recommendations1
Needham
Citizens Capital Markets
HC Wainwright & Co.
RBC Capital
WBB Securities
1calculated from analyst ratings
Analyst Ratings for Cidara Therapeutics
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 04/10/2025 | Buy Now | 82.48% | Needham | Joseph Stringer58% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 03/12/2025 | Buy Now | 139.83% | Citizens Capital Markets | Roy Buchanan34% | → $46 | Initiates | → Market Outperform | Get Alert |
| 03/10/2025 | Buy Now | 82.48% | HC Wainwright & Co. | Ed Arce56% | $24 → $35 | Maintains | Buy | Get Alert |
| 03/07/2025 | Buy Now | 82.48% | Needham | Joseph Stringer58% | $35 → $35 | Reiterates | Buy → Buy | Get Alert |
| 01/27/2025 | Buy Now | — | Cantor Fitzgerald | Eric Schmidt30% | — | Assumes | → Overweight | Get Alert |
| 12/13/2024 | Buy Now | 77.27% | RBC Capital | Gregory Renza45% | → $34 | Initiates | → Outperform | Get Alert |
| 12/05/2024 | Buy Now | 134.62% | WBB Securities | Stephen Brozak71% | $40 → $45 | Maintains | Strong Buy | Get Alert |
| 11/11/2024 | Buy Now | 25.13% | HC Wainwright & Co. | Ed Arce56% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 11/08/2024 | Buy Now | 72.05% | Guggenheim | Seamus Fernandez57% | → $33 | Initiates | → Buy | Get Alert |
| 10/22/2024 | Buy Now | 25.13% | HC Wainwright & Co. | Ed Arce56% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 09/16/2024 | Buy Now | 25.13% | HC Wainwright & Co. | Ed Arce56% | $24 → $24 | Reiterates | Buy → Buy | Get Alert |
| 08/14/2024 | Buy Now | 25.13% | HC Wainwright & Co. | Ed Arce56% | → $24 | Upgrade | Neutral → Buy | Get Alert |
| 08/14/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
| 08/14/2024 | Buy Now | 30.34% | Needham | Joseph Stringer58% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 06/20/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
| 05/16/2024 | Buy Now | 30.34% | Needham | Joseph Stringer58% | $25 → $25 | Reiterates | Buy → Buy | Get Alert |
| 04/25/2024 | Buy Now | 108.55% | WBB Securities | Stephen Brozak71% | → $40 | Maintains | Strong Buy | Get Alert |
| 04/25/2024 | Buy Now | 30.34% | Needham | Joseph Stringer58% | $3 → $25 | Maintains | Buy | Get Alert |
| 04/25/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
| 04/23/2024 | Buy Now | — | Cantor Fitzgerald | Louise Chen52% | — | Reiterates | → Overweight | Get Alert |
| 04/08/2024 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | $120 → $120 | Maintains | Buy | Get Alert |
| 12/07/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | $6 → $120 | Reiterates | Buy → Buy | Get Alert |
| 11/06/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | -84.36% | Needham | Joseph Stringer58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/22/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 09/08/2023 | Buy Now | -84.36% | Needham | Joseph Stringer58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 09/07/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 08/07/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | → Buy | Get Alert |
| 08/04/2023 | Buy Now | -84.36% | Needham | Joseph Stringer58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 08/01/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | → Buy | Get Alert |
| 08/01/2023 | Buy Now | -73.93% | Cantor Fitzgerald | Louise Chen52% | → $100 | Reiterates | Overweight → Overweight | Get Alert |
| 06/26/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/15/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | Buy → Buy | Get Alert |
| 05/12/2023 | Buy Now | -84.36% | Needham | Joseph Stringer58% | → $60 | Reiterates | Buy → Buy | Get Alert |
| 04/18/2023 | Buy Now | -84.36% | Needham | Joseph Stringer58% | → $60 | Reiterates | → Buy | Get Alert |
| 03/24/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | → $120 | Reiterates | → Buy | Get Alert |
| 03/23/2023 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | $130 → $120 | Maintains | Buy | Get Alert |
| 03/08/2023 | Buy Now | -73.93% | Cantor Fitzgerald | Louise Chen52% | → $100 | Reiterates | → Overweight | Get Alert |
| 03/01/2023 | Buy Now | -66.11% | HC Wainwright & Co. | Ed Arce56% | → $130 | Reiterates | → Buy | Get Alert |
| 01/25/2023 | Buy Now | -66.11% | HC Wainwright & Co. | Ed Arce56% | $120 → $130 | Maintains | Buy | Get Alert |
| 05/12/2022 | Buy Now | -68.72% | HC Wainwright & Co. | Ed Arce56% | $150 → $120 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Cidara Therapeutics (CDTX) stock?
The latest price target for Cidara Therapeutics (NASDAQ:CDTX) was reported by Needham on April 10, 2025. The analyst firm set a price target for $35.00 expecting CDTX to rise to within 12 months (a possible 82.48% upside). 20 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Cidara Therapeutics (CDTX)?
The latest analyst rating for Cidara Therapeutics (NASDAQ:CDTX) was provided by Needham, and Cidara Therapeutics reiterated their buy rating.
When was the last upgrade for Cidara Therapeutics (CDTX)?
The last upgrade for Cidara Therapeutics Inc happened on August 14, 2024 when HC Wainwright & Co. raised their price target to $24. HC Wainwright & Co. previously had a neutral for Cidara Therapeutics Inc.
When was the last downgrade for Cidara Therapeutics (CDTX)?
There is no last downgrade for Cidara Therapeutics.
When is the next analyst rating going to be posted or updated for Cidara Therapeutics (CDTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Cidara Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Cidara Therapeutics was filed on April 10, 2025 so you should expect the next rating to be made available sometime around April 10, 2026.
Is the Analyst Rating Cidara Therapeutics (CDTX) correct?
While ratings are subjective and will change, the latest Cidara Therapeutics (CDTX) rating was a reiterated with a price target of $35.00 to $35.00. The current price Cidara Therapeutics (CDTX) is trading at is $19.18, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.
